NO981592L - Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten - Google Patents

Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Info

Publication number
NO981592L
NO981592L NO981592A NO981592A NO981592L NO 981592 L NO981592 L NO 981592L NO 981592 A NO981592 A NO 981592A NO 981592 A NO981592 A NO 981592A NO 981592 L NO981592 L NO 981592L
Authority
NO
Norway
Prior art keywords
rar
gamma
apoptosis rate
specific agonist
agonist ligand
Prior art date
Application number
NO981592A
Other languages
English (en)
Norwegian (no)
Other versions
NO981592D0 (no
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of NO981592D0 publication Critical patent/NO981592D0/no
Publication of NO981592L publication Critical patent/NO981592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO981592A 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten NO981592L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Publications (2)

Publication Number Publication Date
NO981592D0 NO981592D0 (no) 1998-04-07
NO981592L true NO981592L (no) 1998-06-09

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Country Status (16)

Country Link
US (4) US6593359B1 (ru)
EP (1) EP0854710A2 (ru)
JP (1) JP3135266B2 (ru)
KR (1) KR19990064139A (ru)
CN (1) CN1121857C (ru)
AU (1) AU705993B2 (ru)
BR (1) BR9610967A (ru)
CA (1) CA2231561A1 (ru)
FR (1) FR2739557B1 (ru)
HU (1) HUP9900453A3 (ru)
NO (1) NO981592L (ru)
NZ (1) NZ319646A (ru)
PL (1) PL185826B1 (ru)
RU (1) RU2188037C2 (ru)
TR (1) TR199800645T1 (ru)
WO (1) WO1997013505A2 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
CN1511519A (zh) 1997-11-12 2004-07-14 - 2型t辅助细胞介导的免疫病的治疗
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
WO2005092283A1 (en) * 2004-03-26 2005-10-06 Dsm Ip Assets B.V. Composition comprising an hdac inhibitor in combination with a retinoid
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) * 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
ES2427980T3 (es) 2008-12-22 2013-11-05 Myoscience, Inc. Sistema crioquirúrgico integrado con refrigerante y fuente de energía eléctrica
WO2012030919A2 (en) * 2010-09-01 2012-03-08 Thomas Jefferson University Composition and method for muscle repair and regeneration
KR102164567B1 (ko) * 2011-06-24 2020-10-12 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료
WO2013106860A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Cryogenic probe filtration system
US9241753B2 (en) 2012-01-13 2016-01-26 Myoscience, Inc. Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
WO2013106859A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Cryogenic needle with freeze zone regulation
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
CN105208954B (zh) 2013-03-15 2019-06-04 肌肉科技股份有限公司 低温钝性解剖方法和设备
US10016229B2 (en) 2013-03-15 2018-07-10 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
WO2015069792A1 (en) 2013-11-05 2015-05-14 Myoscience, Inc. Secure cryosurgical treatment system
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
EP3454762B1 (en) 2016-05-13 2024-04-03 Pacira CryoTech, Inc. Systems for locating and treating with cold therapy
CN109310763B (zh) * 2016-06-10 2022-10-21 Io治疗公司 用于癌症免疫疗法的受体选择性类视黄醇和rexinoid化合物和免疫调节剂
AU2018301830B2 (en) 2017-07-13 2021-08-26 Io Therapeutics, Inc. Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
JP2020532537A (ja) 2017-08-31 2020-11-12 アイオー セラピューティクス インコーポレイテッド がん免疫治療法のための免疫調節物質と併せたｒａｒ選択的アゴニスト
EP3709918A4 (en) 2017-11-15 2021-08-11 Pacira CryoTech, Inc. INTEGRATED COLD THERAPY AND ELECTRIC STIMULATION SYSTEMS FOR LOCALIZATION AND TREATMENT OF NERVE AND RELATED PROCEDURES
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
AU701790B2 (en) * 1995-07-17 1999-02-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}

Also Published As

Publication number Publication date
EP0854710A2 (fr) 1998-07-29
US6593359B1 (en) 2003-07-15
US6506796B1 (en) 2003-01-14
RU2188037C2 (ru) 2002-08-27
AU7220996A (en) 1997-04-30
FR2739557A1 (fr) 1997-04-11
HUP9900453A3 (en) 1999-11-29
AU705993B2 (en) 1999-06-03
JPH11501661A (ja) 1999-02-09
CA2231561A1 (fr) 1997-04-17
NZ319646A (en) 2000-08-25
WO1997013505A3 (fr) 1997-05-29
PL326077A1 (en) 1998-08-17
NO981592D0 (no) 1998-04-07
HUP9900453A2 (hu) 1999-05-28
JP3135266B2 (ja) 2001-02-13
BR9610967A (pt) 1999-03-02
US20010018456A1 (en) 2001-08-30
PL185826B1 (pl) 2003-08-29
CN1121857C (zh) 2003-09-24
WO1997013505A2 (fr) 1997-04-17
KR19990064139A (ko) 1999-07-26
CN1203528A (zh) 1998-12-30
FR2739557B1 (fr) 1997-11-14
US6686386B1 (en) 2004-02-03
TR199800645T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
NO981592L (no) Anvendelse av &lt;gamma&gt;-RAR-spesifikk agonistligand for Õ °ke apoptosisraten
NO981038D0 (no) Glykolbasert borevæske
NO974511D0 (no) Deteksjon av mulig ulovlig kommunikasjonsbruk
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
NO992585D0 (no) MÕling av gasstr°mningsrate
HUP9900037A3 (en) Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis
FI930636A (fi) Foerfarande foer framstaellning av en flerstegspolymer
NO982462D0 (no) MÕling av fyllingsgrad
NO921402L (no) Tankagitator for tidlig hydratisering av konsentrert, flytende, geledannende middel
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
NO983298L (no) System for Õ begrense bruk av et mÕleapparat
NO934066D0 (no) Middel til hindring av polymeravleiring
FI930800A0 (fi) Foerfarande foer avlaegsning av laett oxiderbara organiska foereningar fraongasstroemmar
DE69309191D1 (de) Thermistor-Flüssigkeitsdetektor
FI931482A0 (fi) Foerfarande foer framstaellning av en ziegler-natta-katalysator
ID18290A (id) Detektor batas cairan
FI963532A0 (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
NO20006444L (no) Referanseforbindelse for anvendelse i ananlyser av levosimendanporsjoner
NO970126D0 (no) Anvendelse av benzaldhyder for markering av hydrokarboner
DE29517283U1 (de) Puderdusche
NO994250D0 (no) Cash (caspasehomolog) med dödseffektordomene, modulatorer for funksjonen til FAS-reseptorer
NO940190D0 (no) Anvendelse av x-ketoglutarat
KR970701546A (ko) 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)
NO931713D0 (no) Maaling av flerfase-fluidumstroemning
FI932409A0 (fi) Samtidig generering och maetning av en friktionselektrisk laddning pao en yta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application